Mouse Anti-Human VEGFR-2/KDR
Slide this table
Cat-Nr. | 101-M32 |
Size | 100 µg |
Price | 240 € |
Category | Monoclonal Antibody |
Clone Nr. | (#3(4H3)) |
Isotype | IgG1 |
Species Reactivity | Human |
Formulation | lyophilized |
Buffer | PBS |
Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
Preparation | The monoclonal antibody was produced with the help of BALB/c mice using recombinant human soluble extracellular KDR (110 kDa) as the immunizing antigen. Mouse IgG1 antibody (clone 3 (4H3)) from hybridomas was purified from cell culture supernatant by Protein G chromatography. |
Antigen | recombinant human soluble extracellular KDR (D7) |
Application | WB, FC, E |
Synonyms | vascular endothelial growth factor receptor-2 ; KDR; FLK1; CD309; VEGF receptor 2; VEGFR2; kinase insert domain protein receptor |
Description | VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. Human VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis. |
Uniprot ID | P35968 |
Protein RefSeq | NP_002244.1 |
mRNA RefSeq | NM_002253.2 |
Figures

Consecutive sections of unfixed, human foreskin. A) Staining with anti-soluble VEGFR2/KDR antibodies (#102-PA19). Note signal in epidermis and vessels. B) Staining with anti-membrane-bound VEGFR-2/KDR (#101-M32). Note staining in vessels. C) Negative control. Note non-specific fluorescence in the hornified layer of the epithelium.
Provided by Prof. J. Wilting, Göttingen, Germany.


FACS analysis of VEGFR-2/KDR expression in HUVE cells (upper level) and EPCs derived from PBMcs (lower level) [5µg/ml #101-M32; 5µg/ml PE goat anti-mouse IgG].
The experiment was performed by Trisha M. Westerhof, University of California, Irvine.

FACS analysis of VEGFR-2/KDR expression in human primary dermal microvascular and umbilical vein endothelial cells.

Up-regulation of VEGFR-2 in primary HUVECs by bFGF. Freshly isolated HUVECs (passage 1) were cultured in EBM. Subconfluent cultures were stimulated with VEGF (5 ng/ml) or bFGF (10 ng/ml) for 3 days. Total lysate was prepared and subjected to immunoprecipitation (anti-human VEGFR-2 [#101-M32] followed by Western blotting (anti-human VEGFR-2 [#101-M34].
Bernhard Barleon et. al., unpublished data

IF double staining of human KDR in a co-culture of PAE-Flt-1, PAE-KDR and PAE-FLT-4 with (A) mouse anti-human KDR [#101-M32], (B) rabbit anti-human KDR [B, #102-PA18AG], (C) DAPI and (D) merged. Conjugated secondary antibody: goat anti-rabbit ALEXA Flour (1:600) [Dianova] and goat anti-mouse PE [Santa Cruz].

Total lysate from PAE/KDR cells was measured for expression of VEGFR-1/KDR by a standard Sandwich ELISA using a mouse monoclonal anti-human VEGFR-1 antibody (#101-M32) for capturing and a Biotin conjugated rabbit polyclonal anti-human VEGFR-1 antibody (#102-PABi18) for detection. Total lysate from PAE/Flt-1 and PAE/FLT-4 was used as negative control. As positive control total lysate from PAE/Flt-1 was spiked with recombinant human sKDR.

VEGFR-2/KDR Sandwich-ELISA using soluble KDR (D7) [Cat# S01-002] as standard. Mouse anti-human VEGFR-2 [Cat# 101-M32] was used as capture antibody, biotinylated rabbit anti-human VEGFR-2 [Cat# 102-PABi18] was used for detection.
Reference
- DNA methylation regulates expression of VEGF-R2 (KDR) and VEGF-R3 (FLT4). H. Quentmeier et al., BMC Cancer. 2012; 12: 19.
- VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr407 phosphorylation. B. Herzog et al., Mol Biol Cell. 2011 Aug 1; 22(15): 2766–2776.
- Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. S. Norgall et al., BMC Cancer. 2007; 7: 105.
- Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization. Nowak G. et al., Circulation. 2004 Dec 14;110(24):3699-707.
All prices plus VAT + possible delivery charges